 "FDA head says working with India to improve drug quality, safety")
The U.S. Food and Drug Administration is working with Indian regulators to enhance the quality and safety of drugs made there, the FDA's Commissioner Margaret Hamburg said on Tuesday.
Hamburg also urged Indian regulators to work closely with their foreign peers.
Hamburg was speaking to reporters at the end of a visit to India which follows FDA decisions to ban the shipment of drugs to the United States from plants of leading Indian drugmakers including Ranbaxy Laboratories Ltd and Wockhardt Ltd .
During a visit that started on February 10, Hamburg met the Indian drugs regulator and health ministry officials as well as executives of local drugmakers.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app